Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxford BioSciences Jonathan Fleming And Chris Kim On Investing in Korea: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

All eyes are on the Korea-Seoul Life Science Fund to see how the collaboration between the Boston-based venture capital firm Oxford Biosciences, Korea’s Hanwha Venture Capital, the Seoul Metropolitan Government and the Korea Institute for Advancement of Technology under the Ministry of Knowledge Economy will evolve.

Advertisement

Related Content

Merck Lands Late-Stage Enbrel Biosimilar In Deal With South Korea's Hanwha
As Korea Pharmas Look To U.S., U.S. VC Looks To Korea
Korea Targets Biologics, Devices, Health Care Among Economic Growth Projects For Next Decade

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC080729

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel